PEMBROLIZUMAB VS PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED NSCLC WITH PD-L1 TUMOR PROPORTION SCORE ≥50%.

In the randomized, open-label, phase III KEYNOTE-024 study, pembrolizumab significantly improved progression-free survival and overall survival (OS) compared with platinum-based chemotherapy in patients with previously untreated advanced non-small-cell lung cancer (NSCLC) with a programmed death ligand 1 tumor proportion score of 50% or greater and without EGFR/ALK aberrations. We report an updated OS and tolerability […]

PEMBROLIZUMAB VS PLATINUM-BASED CHEMOTHERAPY FOR ADVANCED NSCLC WITH PD-L1 TUMOR PROPORTION SCORE ≥50%. Read More »